India Gives Green Light to Qdenga – First Dengue Vaccine Covering All Four Strains

In a move that health officials are calling a "milestone for public‑health," the Drug Controller General of India (DCGI) gave market authorisation to Qdenga – Takeda’s dengue vaccine – on 20 July 2026. The approval, formalised through the CDSCO, means India now has its first licensed vaccine that can tackle all four dengue virus serotypes.

Qdenga, officially the dengue tetravalent live‑attenuated vaccine, was developed by Takeda GmbH in Germany and will be imported by Takeda Biopharma India. It is slated for individuals between 4 years and 60 years of age, with no requirement for a prior dengue‑infection test. The schedule is simple: two sub‑cutaneous injections, spaced three months apart.

Regulators based their decision on a global data set that includes more than 28,000 volunteers in eight countries, and a pivotal Phase III trial (DEN‑302) conducted right here in India. The study showed the vaccine to be safe, well‑tolerated and capable of generating an immune response against DENV‑1, DENV‑2, DENV‑3 and DENV‑4.

Beyond the numbers, the vaccine already carries World Health Organization pre‑qualification – a badge that signals it meets international safety and efficacy standards. To date, Takeda says over 24 million doses have been distributed across roughly 44 countries, and the company is eyeing a 2027 launch in India once import clearances and pricing are finalised.

Why does this matter? India shoulders about a third of the world’s dengue burden, with more than 100,000 cases reported in 2025 alone. Seasonal outbreaks claim lives and strain hospitals, especially in the monsoon‑hit south and east. Having a vaccine that can be given regardless of previous exposure could dramatically cut the number of severe cases and, ultimately, save lives.

The Ministry of Health and Family Welfare has welcomed the decision, noting that the vaccine will complement ongoing vector‑control measures such as fogging and community clean‑up drives. Officials are still working out the procurement model, but early signals suggest the central government may negotiate bulk pricing to make Qdenga affordable for state‑run immunisation programmes.

In short, the green light for Qdenga marks a new chapter in India’s fight against dengue. As the country prepares for the first shipments later this year, the hope is that a combination of vaccination and traditional control tactics will finally turn the tide on a disease that has haunted the sub‑continent for decades.